-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Verge Genomics, which is committed to using artificial intelligence to drive drug discovery and development and focusing on serious genetic diseases, announced that it has reached a three-year cooperation with Eli Lilly and Company to research and develop treatments for amyotrophic lateral cords.
A new type of treatment for sclerosis (ALS)
.
According to the terms of the agreement, Verge will receive an upfront payment of US$25 million, equity investment and potential near-term payments, an additional milestone value of US$694 million, and possible royalties
.
ALS is also known as "gradual freezing syndrome".
The average life expectancy of patients is about 2 to 5 years.
There is currently no cure for this disease
.
In this collaboration, Verge will use its "all-in-human" platform to discover and verify new targets for ALS
.
This platform is based on a data set of transcriptomes in the brains of patients with a variety of neurodegenerative diseases
.
"Through cooperation with Eli Lilly, we will test the potential of using human data and machine learning to overcome the transformational barriers of challenging and complex biological diseases
.
" said Alice Zhang, CEO and co-founder of Verge Genomics
.
Related reading: Interview with Zhang Xinli, the 35 largest technology innovators of the year: Seeing opportunities, don't be afraid to chase
"Verge Genomics is advancing an innovative method to identify high-potential drug targets
.
They are validated through artificial intelligence algorithms and large human databases
.
Reference materials:
Reference materials: [1] Verge Genomics Announces Three-Year Collaboration With Lilly to Discover and Develop Novel Treatments Using Its AI-Driven All-in-Human Platform.
Retrieved July 8, 2021, from https:// /20210708005085/en/Verge-Genomics-Announces-Three-Year-Collaboration-With-Lilly-to-Discover-and-Develop-Novel-Treatments-Using-Its-AI-Driven-All-in-Human-Platform
Retrieved July 8, 2021, from https:// /20210708005085/en/Verge-Genomics-Announces-Three-Year-Collaboration-With-Lilly-to-Discover-and-Develop-Novel-Treatments-Using-Its-AI-Driven-All-in-Human-Platform